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Conclusion. We identified several coexisting recipient-,Sharing cross-reactive groups of MHC class I improves long-
donor-, and transplant-related risk factors for graft loss fromterm graft survival.
chronic rejection. In this well-matched group of renal trans-Background. Renal transplant loss from chronic rejection
plants, HLA mismatches and shares had a nonreciprocal rela-remains substantial. To increase our understanding of this syn-
tionship. Sharing of HLA antigens, especially CREG of MHCdrome, we identified risk factors predicting late graft loss, with
class I, was associated with improved long-term survival.a special emphasis on the impact of human lymphocyte antigen
(HLA) matching.
Methods. We studied all 654 cadaveric kidney transplants
performed in our center between 1983 and 1996 that had sur- Graft loss from chronic rejection is the major obstacle
vived for more than six months. Eighty-two transplants, lost to successful long-term outcome following renal trans-
because of chronic rejection, were used as the outcome vari-
plantation and results in an increasing number of patientsable. The influence of HLA mismatches and shares on long-
on dialysis who are awaiting a repeat transplant. Bothterm graft survival was evaluated at the level of private antigens
alloantigen-dependent and -independent factors haveand cross-reactive groups (CREG) of multiple histocompatibil-
ity complex (MHC) class I. HLA and other recipient, donors been identified that contribute interactively to the deteri-
and transplant parameters were studied using univariate and oration of graft function and structure that ultimately
multivariate Cox regression analysis. results in graft loss [1, 2]. A high donor age is the best
Results. The cohort had a mean number of 1.9 HLA mis-
recognized antigen-independent factor that affects graftmatches. Because of the homozygosity of HLA antigens, HLA
survival adversely [3, 4], whereas the acute rejection his-mismatches were not reciprocal to shares. CREG and
tory is the most important immunological predictor forHLA-A-B mismatches had a relative risk for graft loss of 1.19
(95% CI, 0.97 to 1.45) and 1.05 (0.84 to 1.32) per mismatch. late graft loss [5, 6]. Specifically, the number of acute
In contrast, the relative risk per shared CREG and broad rejection episodes, their timing, their severity, and their
HLA-A-B antigen was 0.76 (0.63 to 0.92) and 0.79 (0.61 to histological type seem to be important [7–13]. The influ-
1.03). Multivariate analysis revealed that individuals sharing
ence of human leukocyte antigen (HLA) matching onless than four CREGs had a relative risk of 2.13 (1.29 to 3.75)
long-term survival is less clear. The detrimental effectfor late graft loss. Other independent predictors were a recipi-
of HLA disparity between donor and recipient as ob-ent age of less than 50 years, relative risk 1.95 (1.02 to 3.71);
a donor age of more than 50 years, relative risk 1.68 (1.01 to served in large registries [4, 14–17] has not been found
2.80); acute rejection (vascular vs. no rejection), relative risk in most single-center studies [18, 19]. Matching for split
3.52 (1.72 to 7.18); proteinuria (dipstick . 11 vs. negative), HLA antigens has been reported to result in a better
relative risk 2.86 (1.29 to 6.35); and a serum creatinine concen- transplant outcome than matching for broad HLA anti-tration of more than 150 mmol/liter at six months, relative risk
gens [20], but this does not seem practical to implement3.41 (1.96 to 5.94).
because of the enormous polymorphism of the HLA
system. Recently, it has been suggested that matching for
the public HLA epitopes of multiple histocompatibilityKey words: chronic rejection, transplantation, HLA matching, donor
parameters. complex (MHC) class I, also called cross-reactive groups
(CREG), increases the likelihood of recipients to obtainReceived for publication March 8, 1999
histocompatible kidneys [21, 22]. However, the effect ofand in revised form June 14, 1999
Accepted for publication June 16, 1999 CREG matching is still controversial and has not been
fully addressed [23, 24]. 1999 by the International Society of Nephrology
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Table 1. Cross-reactive groups (CREG) used in the present studyThe aim of this study was to identify the recipient-,
donor-, and transplant-related factors predicting late CREG Antigens included
graft loss, with special emphasis on the impact of HLA A01C A1, 3, 11, 29, 30, 31, 36
A02C A2, 23, 24, 28, B57, 58matching.
A10C A25, 26, 32, 33, 34, 66
B05C B18, 35, 51, 52, 53
B07C B7, 8, 13, 27, 41, 47, 55, 56, 60, 61METHODS
B08C B8, 14, 18, 38, 39
B12C B13, 37, 41, 44, 45, 47, 49, 50, 60, 61Patients and immunosuppression
B21C B35, 49, 50, 51, 52, 53, 57, 58, 62, 63, 70
All 654 cadaveric renal transplants done in the Leiden BW4 A23, 24, 25, 32, B13, 27, 37, 38, 44, 47, 49, 51, 52,
53, 57, 58, 63University Medical Center between January 1983 and
BW6 B7, 8, 14, 18, 35, 39, 41, 45, 50, 55, 56, 60, 61, 62, 70July 1996 that had survived at least six months were
included in the study. There were 106 repeat transplants.
Patients were followed until death, return to dialysis, or
until July 1, 1998. The median follow-up was 74 months
specimens obtained beyond the first six months from(range, 6 to 186 months). Kidneys were allocated ac-
patients with late graft loss. Graft histology was evalu-cording to the matching algorithm used by Eurotrans-
ated according the recently published Banff ’97 classifi-plant. In our center, we aimed for no more than two
cation [27].HLA mismatches and, preferably, no DR mismatches.
A number of recipient-, donor-, and transplant-relatedThe standard immunosuppressive regimen consisted of
characteristics were evaluated as risk factors of late graftprednisone and cyclosporine (Sandimmune). Fifty-four
loss. The following recipient variables were tested: age,patients (8.3%) were initially treated with prednisone
original disease, cigarette smoking, pretransplant bloodand azathioprine. Sixty patients (9.2%) in the study were
pressure, peak and current panel reactive antibodies.converted to azathioprine at three-months post-trans-
The original diseases were grouped according to theplant as part of a prospective randomized trial [25];
UNOS report in inherited (polycystic disease, Alport’sanother 51 patients (7.8%) were converted in the first
disease, dysplasia), glomerular (primary glomerulone-six-months post-transplant from cyclosporine to azathio-
phritis), and systemic (nephrosclerosis, diabetes mellitus,prine for clinical reasons, mostly because of suspected
vasculitis, systemic lupus) diseases [4]. The donor vari-cyclosporine toxicity. Beyond three months post-trans-
ables studied were age and cause of death. Transplantplant, the once-daily cyclosporine dose was adjusted to
parameters studied included year of transplant, repeata desired 24-hour trough concentration between 250 and
transplant, gender match, cold ischemic time, delayed500 mg/liter (polyclonal radioimmunoassay; Sandoz, East
graft function defined as the need of dialysis in the firstHanover, NJ, USA) and from 1989 onward to a range of
week, and the baseline immunosuppressive drug regi-50 to 150 mg/liter (monoclonal radioimmunoassay; Incstar,
men. All kidney donors and recipients were typed usingStillwater, MN, USA). During the first six months, acute
the standardized Eurotransplant serum set for HLA-A,rejection episodes occurred in 56% of the cases, and
-B, and -DR antigens. All donors were retyped at thethese were confirmed by biopsies in 88%. Interstitial
Eurotransplant Reference Laboratory [28]. MHC classrejection was diagnosed when tubulitis with a widespread
I antigens were assigned to one or more CREG (Tableinterstitial infiltrate was present; a diagnosis of vascular
1), based on the amino acid residue system proposed forrejection was made when arteritis was present. Rejection
UNOS allocation [21]. We studied the impact of HLAepisodes were treated according to a standard protocol
matching of broad antigens as well as antigenic splitsconsisting of three one-gram intravenous doses of meth-
and CREG. Not only was the degree of mismatchingylprednisolone, a 10-day course of antithymocyte globu-
between donor and recipient studied, but also the effectlin at a dose of 5 mg/kg guided by absolute lymphocyte
of sharing HLA antigens. The term “shares” was usedcounts, or a course of methylprednisolone for the first,
for the number of corresponding HLA antigens betweensecond, or third rejection episode, respectively.
donor and recipient. We made cross-tabulations of HLA
Study design mismatches and shares to investigate their relationship.
Furthermore, we compared the percentage of homozy-Graft loss from chronic rejection was defined as graft
gosity between donors and recipients. We also evaluatedfailure beyond six months and exclusion of other obvious
risk factors observed up to six-months post-transplant.causes of graft loss. Therefore, analysis was censored for
Clinical and histological acute rejection parameters weregraft loss from recurrent or de novo glomerulonephritis,
studied in detail: the number of acute rejection treat-transplant renal artery stenosis or thrombosis, acute re-
ments in the first six months, time to the first and lastjection as result of discontinuation of immunosuppres-
acute rejection episode, and histological type of rejection.sive drugs, or patient death with a functioning graft [26].
Furthermore, we reviewed all biopsies and nephrectomy The occurrence of an acute rejection episode beyond
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Table 2. Demographic, clinical and laboratory characteristics ofsix-months post-transplant was studied as a time-depen-
study subjects
dent variable. Cytomegalovirus (CMV) serology was
Characteristic Valueroutinely performed pretransplant and on clinical indica-
Recipient factorstion after transplantation. The occurrence of CMV sero-
Age years 45612conversion in the first six months was analyzed as a
Gender % female 37
risk factor. As a result of the randomized and clinical Original disease: inherited/glomerular/systemic % 19/40/17
Cigarette smoking % 43conversion from cyclosporine to azathioprine in many
Systolic blood pressure mm Hg 149626patients, the maintenance drug regimen at six months Diastolic blood pressure mm Hg 89613
post-transplant was studied as a separate variable. The Peak panel reactive antibodies % 31632
Current panel reactive antibodies % 11622effect of cyclosporine trough levels could not be evalu-
Donor factorsated because of the mentioned change in assays in 1989. Age years 37615
Therefore, we used the drug dose (mg/kg) at six months Gender % female 40
Cause of death: trauma/cardiovascular % 45/50as a measure in patients on cyclosporine. Blood pressure,
Transplant factorsnumber of antihypertensive drugs, dipstick proteinuria, Year of transplant: 1983–86/1987–91/1992–96 % 30/37/33
serum creatinine, and endogenous creatinine clearance Repeat transplant % 16
Gender: match/female to male/male to female % 54/24/22at six months were evaluated as clinical parameters.
Cold ischemic time hours 2967
Delayed graft function % 24
Statistical analysis Immunosuppression: cyclosporine/azathioprine % 92/8
HLA CREG mismatches 1.1 61.0A cross-tabs procedure and a chi-square test tested
HLA-A, -B and -DR broad mismatches 1.9 61.1
the relationship between HLA mismatches and shares. HLA-A, -B and -DR split mismatches 2.2 61.2
HLA CREG shares 4.5 61.2Late graft loss from chronic rejection was used as the
HLA-A, -B and -DR broad shares 3.6 61.0outcome variable. We used the Cox proportional hazard HLA-A, -B and -DR split shares 3.4 61.1
model to assess the predictive value of the studied risk Acute rejection factors
Histologic type: interstitial/vascular % 34/15factors. The effect of acute rejection episodes occurring
Number of rejection episodes: one/two/three or
after six months was tested as a time-dependent variable. more % 23/22/11
First episode: within one month/between monthSignificant predictors (P , 0.05) of late graft loss in
one and six % 45/11univariate analysis were fitted into a multivariate model.
Last episode: within two months/between month
Other potential confounders such as prior graft loss, three and six % 40/10
Rejection episode(s) after six months % 8panel reactive antibodies, delayed graft function, and
Factors at six months post-transplantHLA mismatches were also added to the analysis. For- Cytomegalovirus: sero-negative/-positive/
ward selection techniques were used to choose significant -conversion % 25/57/18
Systolic blood pressure mm Hg 144620risk factors. The histological type of acute rejection was
Diastolic blood pressure mm Hg 86610used as rejection factor and serum creatinine of more Number of antihypertensive drugs 1.4 60.9
than 150 mmol/liter as renal function parameter. Multi- Immunosuppression: cyclosporine/azathioprine % 77/23
Cyclosporine dose mg/kg 4.661.8variate analysis was performed with and without inclu-
Dipstick proteinuria: trace, 1/. 11 % 42/6
sion of the serum creatinine concentration at six months Serum creatinine lmol/liter 152666
Creatinine clearance ml/min 62623into the model. We used the SPSS software package
(8.0) for all of our analyses. Data are expressed as mean 1 sd unless otherwise stated.
RESULTS
cases, respectively. The median follow-up in the 82 lostThe demographic and clinical characteristics for the
transplants was 34 months (range, 6 to 132 months).entire study population are presented in Table 2. A total
Our cohort of patients studied was well matched forof 224 transplants was lost. Fourteen (6%) were due to
HLA antigens. The mean number of CREG and HLA-A,de novo or recurrent glomerulonephritis. Nine (4%)
-B, -DR mismatches was 1.1 and 1.9, respectively. Cross-were due to thrombosis or stenosis of the transplant
tabulation of mismatches and shares revealed that mis-renal artery. Three (1%) were due to discontinuation of
matches and shares had a nonreciprocal relationship (Ta-immunosuppressive drugs, and 116 (52%) were due to
ble 3). The mean number of CREG and HLA-A, -B,patient death with a functioning graft. After censoring
-DR shares was 4.5 and 3.6. The percentage of homozy-for these causes, late graft loss occurred in 82 (37%)
gosity was higher in the donors compared with the recipi-transplants; in 62 cases, graft histology was available
ents: A locus, 21 versus 17%; B locus, 12 versus 9%; andfrom biopsies or nephrectomy specimens, which showed
DR locus, 20 versus 14%. The quantitative impact ofchronic allograft nephropathy in all cases. Concomitant
borderline or acute rejection was present in 18 and 25 HLA matching on graft loss is shown in Table 4. Although
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Table 4. HLA matching and relative risk of late graft loss usingTable 3A. Cross tabulation of HLA-A, -B, -DR mismatches and
shares (Pearson r 5 0.76) univariate Cox regression analysisa
Relative 95% ConfidenceHLA mismatches
Characteristic risk interval P value
HLA shares 0 1 2 3 4 5 6 Total
Mismatches
0 1 2 3 HLA CREG 1.19 0.97–1.45 0.10
1 1 3 2 6 HLA-A-B broad 1.05 0.84–1.32 0.65
2 1 5 18 34 58 HLA-A-B split 1.05 0.84–1.30 0.67
3 15 24 78 139 256 HLA-DR broad 1.02 0.68–1.53 0.92
4 20 59 143 222 HLA-DR split 1.08 0.75–1.55 0.69
5 20 57 77 HLA-A-B-DR broad 1.04 0.86–1.26 0.67
6 30 30 HLA-A-B-DR split 1.06 0.89–1.27 0.51
Total 85 141 226 159 37 2 2 652 Shares
HLA CREG 0.76 0.63–0.92 0.005
HLA-A-B broad 0.79 0.61–1.03 0.08
Table 3B. Cross tabulation of CREG mismatches and shares HLA-A-B split 0.78 0.61–1.00 0.05
(Pearson r 5 0.45) HLA-DR broad 0.81 0.56–1.19 0.29
HLA-DR split 0.78 0.54–1.12 0.17
CREG mismatches HLA-A-B-DR broad 0.79 0.63–0.99 0.04
HLA-A-B-DR split 0.77 0.62–0.95 0.01CREG shares 0 1 2 3 4 5 Total
a Relative risk calculated per mismatch or share1 4 1 1 6
2 1 6 1 1 9
3 27 25 32 21 4 2 111
4 46 69 59 24 1 199
5 74 72 38 7 191
6 45 36 5 2 88
7 26 7 33
8 5 5
Total 223 210 140 59 7 3 642
a higher number of HLA mismatches did not predict
graft loss, sharing broad HLA-A, -B, -DR antigens had
a beneficial effect on long-term outcome. Matching at
the level of split antigens showed similar results. Sharing
of HLA-DR antigens did not impact on outcome,
whereas the effect of sharing of HLA-A-B antigens was
almost significant. However, sharing CREG of MHC
class I improved the outcome significantly (Fig. 1).
The univariate effects of the various other risk factors
Fig. 1. Graft survival and cross-reactive antigen (CREG) sharing.are shown in Table 5. The relative risk of graft loss was
Kaplan–Meier estimates for transplants sharing 4 to 8 CREG (solidincreased in recipients younger than 50 years. Pretrans- line, N 5 516) and sharing 1 to 3 CREG (dashed line, N 5 126). Log-
rank test, P 5 0.0011.plant blood pressure was not significantly associated with
graft failure. Patients with inherited renal diseases did
better than patients with glomerular or systemic diseases.
Cigarette smoking had a detrimental effect on graft out-
period were more at risk for graft loss compared withcome. Grafts from older donors (over age 50) experi-
the transplants done more recently. We found a strong
enced decreased graft survival. There was no difference
influence of acute rejection on long-term graft survival.
between donors who died from cardiovascular causes or The occurrence of interstitial and especially vascular re-
as a result of a trauma. The gender mismatch factor was jection within six months was associated with poor out-
not associated with an effect on graft loss. Patients who come (Fig. 2). An increasing number and a later occur-
were on an initial immunosuppressive drug regimen not rence of rejection episodes were also associated with
containing cyclosporine did worse compared with pa- graft loss. Acute rejection beyond six months, tested as
tients treated with cyclosporine. No significant long-term a time-dependent variable, had a strong adverse effect
effect was found of the degree of sensitization, duration on graft survival. Patients showing CMV seroconversion,
of cold ischemic time, or delayed graft function. Also, presumably caused by a CMV-positive donor, had com-
first and repeat transplants had an equivalent outcome. parable results to patients with persistent negative CMV
serology. The need of antihypertensive drugs, dipstickTransplants performed in the first five years of the study
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Table 5. Risk factors of late graft loss using univariate Cox regression analysis
Relative 95% Confidence
Characteristic risk interval P value
Recipient factors
Recipient age ,50 years 2.72 1.53–4.84 ,0.001
Original disease: glomerular versus inherited 2.25 1.09–4.67 0.03
Original disease: systemic versus inherited 3.62 1.65–7.92 0.001
Systolic blood pressure per 10 mm Hg increase 1.02 0.93–1.10 0.61
Diastolic blood pressure per 10 mm Hg increase 1.17 0.98–1.39 0.08
Cigarette smoking 1.55 1.00–2.39 0.05
Peak panel reactive antibodies .50% 1.21 0.75–1.95 0.37
Current panel reactive antibodies .50% 1.69 0.87–3.28 0.14
Donor factors
Donor age .50 years 1.88 1.19–2.96 0.007
Cause of donor death: cardiovascular versus trauma 1.24 0.79–1.95 0.42
Transplant factors
Year of transplant: 1987–91 versus 1992–96 1.88 0.91–3.87 0.09
Year of transplant: 1983–86 versus 1992–96 2.67 1.31–5.43 0.007
Repeat transplant 1.24 0.72–2.14 0.43
Gender match: female-to-male versus match 1.53 0.93–2.50 0.09
Gender match: male-to-female versus match 0.97 0.54–1.73 0.93
Cold ischemic time .36 hours 1.43 0.84–2.44 0.19
Delayed graft function 0.90 0.52–1.54 0.69
Immunosuppression: azathioprine versus cyclosporine 1.90 1.06–3.40 0.03
Acute rejection factors
Acute rejection type: interstitial 2.36 1.33–4.20 0.003
Acute rejection type: vascular 5.10 2.81–9.28 ,0.001
Number of rejection episodes: one 1.87 0.94–3.36 0.08
Number of rejection episodes: two 3.03 1.68–5.47 ,0.001
Number of rejection episodes: three or more 5.58 2.86–10.1 ,0.001
First rejection episode: within one month 2.22 1.33–3.71 0.02
First rejection episode: between month one and six 4.17 2.18–7.98 ,0.001
Last rejection episode: within two months 0.81 0.48–1.38 0.44
Last rejection episode: between month two and six 5.01 2.97–8.47 ,0.001
Acute rejection episode(s) after six months 5.71 3.46–9.42 ,0.001
Clinical factors at six months post-transplant
Cytomegalovirus: seroconversion versus seronegative 0.78 0.40–1.50 0.45
Systolic blood pressure per 10 mm Hg increase 1.04 0.93–1.17 0.46
Diastolic blood pressure per 10 mm Hg increase 1.28 0.99–1.58 0.06
Number of antihypertensive drugs 1.27 1.00–1.62 0.05
Immunosuppression: azathioprine versus cyclosporine 1.12 0.70–1.81 0.63
Cyclosporine dose ,3 mg/kg 1.55 0.78–3.08 0.21
Dipstick proteinuria: trace, 1 versus negative 2.46 1.48–4.09 ,0.001
Dipstick proteinuria: .11 versus negative 6.26 3.12–12.54 ,0.001
Serum creatinine .150 lmol/liter 4.37 2.72–7.00 ,0.001
Creatinine clearance ,50 ml/min 4.18 2.69–6.51 ,0.001
proteinuria, and an elevated serum creatinine concentra- DISCUSSION
tion (.150 mmol/liter) at six-months post-transplant was The aim of this study was to identify risk factors pre-
also associated with a higher risk of graft loss. dicting late graft loss in renal transplant patients. We
The result of the multivariate analysis is given in Table found that a higher number of HLA mismatches did
6. It shows that recipients younger than 50 years were not predict graft loss, whereas sharing of HLA antigens,
at risk for late graft loss. Recipients with an inherited especially MHC class I CREG, had a beneficial effect
original disease had a favorable outcome. The detrimen- on long-term outcome. In contrast to North American
tal effect of grafts from donors older than 50 years was databases, our cohort of patients was very well matched.
only present after discarding renal function at six months Therefore, it is not surprising that the mismatch level
from the model. Sharing less than four CREG and a did not further affect long-term survival. Even when
baseline immunosuppressive regimen consisting of pred- HLA antigenic splits were considered in the evaluation,
nisone and azathioprine predicted late graft loss inde- the outcome did not correlate with the degree of mis-
pendent from acute rejection. The negative effect of matching. However, we clearly demonstrated that HLA
acute rejection on outcome was especially present in mismatches and shares had a nonreciprocal relationship.
case of vascular rejection. Proteinuria and renal dysfunc- This phenomenon is explained by homozygosity of HLA
specificities and the allocation algorithm aiming at a lowtion at six months were independent clinical factors.
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should reveal whether or not allocation algorithms based
on CREG matching would reduce the number of failed
grafts.
Recipient-, donor-, and transplant-related factors all
influenced outcome. After censoring for death with a
functioning graft, recipients younger than 50 years were
more likely to have late graft loss compared with older
recipients [26]. This observation is consistent with other
studies that have shown that young age is associated
with a state of heightened immune responsiveness to
alloantigens [38]. Moreover, young patients tend to have
a lower compliance with prescribed drugs [39]. Another
important factor in late graft loss is the age of the donor.
The use of kidneys from older donors is correlated with
an increased risk of late graft loss. Donor age influences
the initial renal function and possibly also the quality of
the tissue [40]. The detrimental effect of a higher donorFig. 2. Graft survival and acute rejection type. Kaplan–Meier estimates
for transplants without rejection (solid line, N 5 292), interstitial rejec- age appears to be mediated by a decreased renal mass,
tion (dash dot dash line, N 5 222) and vascular rejection (dashed line, as suggested by our observation that this risk was inde-N 5 95) within six-months post-transplant. Log-rank test, P 5 0.0026,
pendent only after discarding renal function at sixinterstitial vs. no rejection; P , 0.001 vascular vs. no rejection; P 5
0.0038, vascular vs. interstitial rejection. months from the multivariate model. Contrary to some
earlier reports that showed no impact of smoking [41],
in this study, smoking significantly increased the risk of
graft loss. Interestingly, smoking is also an emerging risk
number of mismatches, and was confirmed by a higher factor in other nontransplant renal diseases [42]. Patients
percentage of homozygosity of the different HLA loci in with inherited renal diseases such as polycystic disease
the donors. This finding is important because a significant did better than patients with systemic or glomerular dis-
long-term beneficial effect of histocompatibility was only ease, which is in agreement with large registry data [4].
apparent in the analyses of shared HLA antigens. The From our study, it appears that the occurrence of late
beneficial effect of sharing HLA antigens has been re- graft loss decreases over the long course of the study
ported [29, 30] and is illustrated by the excellent survival period. Indeed, patients receiving azathioprine as the
of six-antigen shared grafts [31]. However, the difference baseline immunosuppressive regimen did worse than pa-
between shares and mismatches with respect to their tients on a cyclosporine-based regimen. These findings
effect on graft survival has not been demonstrated pre- might be partially explained by the higher incidence of
viously in the same study population. HLA-A and vascular rejection in the azathioprine-treated patients
HLA-B matching seems to have a more profound effect [9]. On the other hand, conversion from cyclosporine to
on long-term survival compared with HLA-DR match- azathioprine in the first six months is safe [25]. We could
ing [32, 33]. Private class I antigens share antigenic deter- not demonstrate an effect on late graft failure of pre-
minants that can be assigned in public groups, also called transplant sensitization to lymphocyte antigens, ischemic
CREG [21, 22, 29, 34, 35]. We found a beneficial effect damage, and repeat transplantation. These variables are
of sharing CREG on long-term graft survival that was probably more related to early graft loss, with little effect
independent from acute rejection in the multivariate on long-term survival [15, 43].
analysis. A minimum of four shared CREG seems to be At six-months post-transplant, pending graft loss could
required for optimal graft survival. This result extends be independently predicted by the histological pattern
a recent report that showed that CREG matching was of previous acute rejection episodes, confirming previous
associated with a reduced frequency of late rejection data from our center and others that vascular rejection
episodes and improved two-year graft function [23]. It is a strong risk factor for late graft loss [9, 44]. The inci-
has been suggested that self-restricted recognition of do- dence of vascular rejection should be a valuable short-
nor-derived HLA peptides contributes to the pathogene- term endpoint in clinical trials comparing different immu-
sis of chronic rejection [36, 37]. Both mismatches and nosuppressive regimens. Patients with multiple and late
shares might play a role in this indirect allorecognition acute rejection episodes also showed an increased risk
pathway. A low number of mismatches reduces the num- for late graft loss, as shown previously [7, 8, 10, 11, 13].
ber of foreign peptides presented. Shared HLA antigens Proteinuria is not only an important prognostic factor
might result in down-regulation or clonal deletion of T of outcome [45], it may also play a role in the pathogene-
sis of renal injury [46]. Maneuvers to reduce proteinuriacells directed to these peptides. Prospective studies
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Table 6. Independent risk factors of late graft loss using multivariate Cox regression analysis
Relative 95% Confidence
Characteristic risk interval P value
Recipient age ,50 years 1.95 1.02–3.71 0.04
Original disease: glomerular versus inherited 2.59 1.05–6.38 0.04
Original disease: systemic versus inherited 4.99 1.91–13.1 0.001
Donor age .50 yearsa 1.68 1.01–2.80 0.04
Sharing HLA CREG (1–3 versus 4–8) 2.20 1.29–3.75 0.004
Immunosuppression: azathioprine versus cyclosporine 2.13 1.06–4.28 0.03
Acute rejection: interstitial versus no rejection 2.04 1.04–3.97 0.04
Acute rejection: vascular versus no rejection 3.52 1.72–7.18 0.001
Proteinuria at six months (.11dipstick versus negative) 2.86 1.29–6.35 0.01
Serum creatinine at six months .150 lmol/liter 3.41 1.96–5.94 ,0.001
a Donor age is an independent risk factor after removal of serum creatinine from the model
2. Carpenter CB: Long-term failure of renal transplants: Addingmay stabilize deteriorating graft function and may ulti-
insult to injury. Kidney Int 48(Suppl 50):S40–S44, 1995mately affect prognosis [47]. The serum creatinine con- 3. Chertow GM, Milford EL, Mackenzie HS, Brenner BM: Anti-
centration at six months was strongly correlated with gen-independent determinants of cadaveric kidney transplant fail-
ure. JAMA 276:1732–1736, 1996subsequent graft loss.
4. Gjertson DW: Look-up survival tables for renal transplantation,Although there is no direct clinical test to diagnose in Clinical Transplants, edited by Cecka JM, Terasaki PI, Los
chronic rejection, the gradual deterioration in graft struc- Angeles, UCLA Tissue Typing Laboratory, 1997, pp 337–383
5. Tesi RJ, Henry ML, Elkhammas EA, Ferguson RM: Predictorsture and function as a result of antigen-dependent mech-
of long-term primary cadaveric transplant survival. Clin Transplantanisms, it seems to constitute the predominant cause of
7:345–352, 1993
late graft loss in our study population. We studied only 6. Cole E, Naimark D, Aprile M, Wade J, Cattran D, Pei Y, Fenton
patients with graft survival beyond six months, a point S, Robinette M, Zaltsman J, Bear R, Cardella C: An analysis
of predictors of long-term cadaveric renal allograft survival. Clinin time at which most graft failures from acute rejection
Transplant 9:282–288, 1995have occurred. Chronic rejection was diagnosed by exclu- 7. Gulanikar AC, MacDonald AS, Sungurtekin U, Belitsky P:
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